Showing 7761-7770 of 10799 results for "".
- FDA Approves Once-Daily Oral Semaglutidehttps://practicaldermatology.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- TOGETHER-PsA: Weight Loss Plus PsA Control with Ixekizumab and Tirzepatidehttps://practicaldermatology.com/news/together-psa-weight-loss-plus-psa-control-with-ixekizumab-and-tirzepatide/2485259/In the phase 3b TOGETHER-PsA trial, ixekizumab (Taltz, Eli Lilly) used in combination with tirzepatide (Zepbound, Eli Lilly) was more effective than ixekizumab monotherapy in adults with active psoriatic arthritis (PsA) who also have obesity or are overweight with a
- Analysis Suggests Possible 'Oral–Gut–Skin Axis' in HShttps://practicaldermatology.com/news/analysis-suggests-possible-oralgutskin-axis-in-hs/2485169/New microbiome research comparing acne and hidradenitis suppurativa (HS) across multiple anatomical sites shows unique microbial signatures that may aid researchers in explaining the chronic HS phenotype. The study authors ana
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://practicaldermatology.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- Study Links BMI and IBD Causally to Hidradenitis Suppurativahttps://practicaldermatology.com/news/mendelian-randomization-study-links-bmi-and-ibd-causally-to-hidradenitis-suppurativa/2485068/A new mendelian randomization (MR) analysis provides genetic evidence supporting a causal role for elevated body mass index (BMI) and inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS). Study researchers used gen
- First Patient Enrolled in Nemolizumab Study for Chronic Itch Without Causehttps://practicaldermatology.com/news/first-patient-enrolled-in-nemolizumab-study-for-chronic-itch-without-cause/2484883/Galderma announced the enrollment first patient in a phase II clinical trial investigating nemolizumab for the treatment of Chronic Pruritus of Unknown Origin (CPUO), according to a press release from the manufacturer. The tr
- New Series Spotlights Real Stories of MCC Patientshttps://practicaldermatology.com/news/new-series-spotlights-real-stories-of-mcc-patients/2484808/The Skin Cancer Champions Community announced that it will launch its Living With: Merkel Cell Carcinoma (MCC) web series on Wednesday, January 14, 2026, from 12:00 to 1:00pm EST via Zoom. According to a release from the group, the premiere episode,
- Analysis: Machine Learning Model Outperforms Existing Melanoma Prognostic Toolshttps://practicaldermatology.com/news/analysis-machine-learning-model-outperforms-existing-melanoma-prognostic-tools/2484593/A new machine learning-based model may offer clinicians a more accurate method for predicting prognosis in patients with cutaneous melanoma, according to a study published in Experimental Dermatology.
- SCRATCH-AD: Rapid-Onset Anti-Itch and Anti-Inflammatory Effects of Ruxolitinib Creamhttps://practicaldermatology.com/news/scratch-ad-rapid-onset-anti-itch-and-anti-inflammatory-effects-of-ruxolitinib-cream/2484591/Results from the SCRATCH-AD study suggested that ruxolitinib cream 1.5% provided itch relief, as well as broader improvements in atopic dermatitis (AD) severity The SCRATCH-AD study evaluated how quickly ruxolitinib 1.5% cream
- Stapokibart Shows Efficacy and Safety in Elderly Patients With ADhttps://practicaldermatology.com/news/stapokibart-shows-efficacy-and-safety-in-elderly-patients-with-ad/2484589/This post hoc analysis evaluated the efficacy and safety of stapokibart, an anti–IL-4Rα monoclonal antibody, in elderly adults with moderate-to-severe atopic dermatitis—a population often characterized by more complex inflammatory signatures and comorbidities. The